Bayer (BAYN) Given a €78.00 Price Target at Goldman Sachs Group
Bayer (FRA:BAYN) has been given a €78.00 ($90.70) target price by stock analysts at Goldman Sachs Group in a research note issued to investors on Tuesday. The brokerage currently has a “buy” rating on the healthcare company’s stock. Goldman Sachs Group’s price objective would suggest a potential upside of 14.24% from the stock’s current price.
Several other analysts have also recently issued reports on BAYN. Sanford C. Bernstein set a €89.00 ($103.49) price target on shares of Bayer and gave the stock a “buy” rating in a research report on Monday, October 15th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Bayer in a research report on Monday, October 22nd. Jefferies Financial Group set a €77.00 ($89.53) target price on shares of Bayer and gave the stock a “neutral” rating in a research note on Tuesday, October 23rd. equinet set a €96.00 ($111.63) target price on shares of Bayer and gave the stock a “buy” rating in a research note on Tuesday, October 23rd. Finally, UBS Group set a €122.00 ($141.86) target price on shares of Bayer and gave the stock a “buy” rating in a research note on Tuesday, October 23rd. Seven equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of €88.37 ($102.76).
Shares of BAYN opened at €68.28 ($79.40) on Tuesday. Bayer has a 1 year low of €91.58 ($106.49) and a 1 year high of €123.82 ($143.98).
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
See Also: What is the float in trading stocks?
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.